Sartorius, a Goettingen, Germany-headquartered pharmaceutical and laboratory equipment supplier, has acquired two bioanalytical companies: Essen BioScience, headquartered in Ann Arbor, Michigan, for $320 million and MKS Instruments AB (Umetrics), headquartered in Malmö, Sweden, for $72.5 million.

Sartorius closed on its previously announced acquisition of Essen BioScience, a provider of cell-based assays and instrumentation for drug discovery and basic research applications, from SFW Capital Partners, a Rye, New York-based private equity firm, in April 2017 after receiving antitrust clearance. Sartorius announced the acquisition in March 2017. Essen BioScience’s real-time live-cell imaging and analysis systems expands Sartorius Lab Products & Services Division’s portfolio in bioanalytics, which Sartorius entered last year with its June 2016 $90-million acquisition of IntelliCyt, a manufacturer of cell-screening platforms used in drug discovery. For the current fiscal year, Essen BioScience expects to generate annual sales revenue of around $60 million.

Sartorius acquired Umetrics through its subgroup, Sartorius Stedim Biotech, from the US MKS Instruments Group. Umetrics specializes in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes. Umetrics has been cooperating with Sartorius for around five years and plans to generate full-year sales revenue of approximately $15 million in 2017.

Source: Sartorius